Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2015 Filed Mar 7, 2015 00:19 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 200 | $34.65 | $6,930.00 |
DisclosureSEC source: 0001225208-15-007187 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,475,457 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 4, 2014. Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:19 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 200 | $34.66 | $6,932.00 |
DisclosureSEC source: 0001225208-15-007187 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,475,657 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 4, 2014. Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:19 UTC |
READ IAN CDirector · Chairman & CEO
|
SaleCommon Stock | 100 | $34.81 | $3,481.00 |
DisclosureSEC source: 0001225208-15-007187 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,475,857 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 4, 2014. Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 30,700 | $34.48 | $1,058,536.00 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 10 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,911 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 7,939 | $34.47 | $273,657.33 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 9 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,611 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 4,500 | $34.46 | $155,070.00 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 8 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,550 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 3,659 | $34.44 | $126,015.96 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 7 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,050 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 3,000 | $34.42 | $103,260.00 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,709 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 2,500 | $34.41 | $86,025.00 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,709 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 2,400 | $34.40 | $82,560.00 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,209 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 2,000 | $34.43 | $68,860.00 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,609 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 1,200 | $34.49 | $41,388.00 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,609 Read SEC document |
| March 05, 2015 Filed Mar 7, 2015 00:32 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 400 | $34.45 | $13,780.00 |
DisclosureSEC source: 0001225208-15-007188 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,809 Read SEC document |
| February 27, 2015 Filed Mar 2, 2015 23:39 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 68 | $34.32 | $2,333.76 |
DisclosureSEC source: 0001225208-15-006384 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,409 Underlying: Common Stock · 68 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 20,134 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · derivative · entry 10 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,134 Underlying: Common Stock · 20,134 shares Expires 2022-02-26 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 24,155 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · derivative · entry 9 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,155 Underlying: Common Stock · 24,155 shares Expires 2020-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · nonDerivative · entry 6 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,246 F7 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
BOURLA ALBERTGroup President
|
GrantStock Appreciation Rights · Derivative | 73,826 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006192 · doc4.xml · derivative · entry 9 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,826 Underlying: Common Stock · 73,826 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
BOURLA ALBERTGroup President
|
GrantStock Appreciation Rights · Derivative | 88,567 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006192 · doc4.xml · derivative · entry 8 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,567 Underlying: Common Stock · 88,567 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 120,805 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006194 · doc4.xml · derivative · entry 9 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,805 Underlying: Common Stock · 120,805 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 144,928 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006194 · doc4.xml · derivative · entry 8 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,928 Underlying: Common Stock · 144,928 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 120,805 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006195 · doc4.xml · derivative · entry 9 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,805 Underlying: Common Stock · 120,805 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 144,928 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006195 · doc4.xml · derivative · entry 8 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,928 Underlying: Common Stock · 144,928 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
Germano Geno JGroup President
|
GrantStock Appreciation Rights · Derivative | 120,805 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006196 · doc4.xml · derivative · entry 10 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,805 Underlying: Common Stock · 120,805 shares Expires 2022-02-26 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:27 UTC |
Germano Geno JGroup President
|
GrantStock Appreciation Rights · Derivative | 144,928 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006196 · doc4.xml · derivative · entry 9 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,928 Underlying: Common Stock · 144,928 shares Expires 2020-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 27,852 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006198 · doc4.xml · derivative · entry 9 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,852 Underlying: Common Stock · 27,852 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 33,414 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006198 · doc4.xml · derivative · entry 8 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,414 Underlying: Common Stock · 33,414 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 60,403 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006197 · doc4.xml · derivative · entry 9 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,403 Underlying: Common Stock · 60,403 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 72,464 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006197 · doc4.xml · derivative · entry 8 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,464 Underlying: Common Stock · 72,464 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 73,826 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006199 · doc4.xml · derivative · entry 9 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,826 Underlying: Common Stock · 73,826 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 88,567 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006199 · doc4.xml · derivative · entry 8 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,567 Underlying: Common Stock · 88,567 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 60,403 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006200 · doc4.xml · derivative · entry 9 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,403 Underlying: Common Stock · 60,403 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 72,464 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006200 · doc4.xml · derivative · entry 8 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,464 Underlying: Common Stock · 72,464 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:49 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 27,852 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006202 · doc4.xml · derivative · entry 9 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,852 Underlying: Common Stock · 27,852 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:49 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 33,414 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006202 · doc4.xml · derivative · entry 8 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,414 Underlying: Common Stock · 33,414 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 48,658 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006201 · doc4.xml · derivative · entry 9 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,658 Underlying: Common Stock · 48,658 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:42 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 58,374 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006201 · doc4.xml · derivative · entry 8 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,374 Underlying: Common Stock · 58,374 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:50 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 402,685 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006203 · doc4.xml · derivative · entry 10 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,685 Underlying: Common Stock · 402,685 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:50 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 483,092 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006203 · doc4.xml · derivative · entry 9 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,092 Underlying: Common Stock · 483,092 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:56 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 60,403 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006204 · doc4.xml · derivative · entry 9 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,403 Underlying: Common Stock · 60,403 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:56 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 72,464 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006204 · doc4.xml · derivative · entry 8 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,464 Underlying: Common Stock · 72,464 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:56 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 120,805 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006205 · doc4.xml · derivative · entry 10 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,805 Underlying: Common Stock · 120,805 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 26, 2015 Filed Feb 27, 2015 23:56 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 144,928 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-15-006205 · doc4.xml · derivative · entry 9 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,928 Underlying: Common Stock · 144,928 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 32,939 | $0.00 Strike: $17.69 | $0.00 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · derivative · entry 8 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,939 shares Expires 2015-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 12,981 | $33.47 | $434,474.07 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · nonDerivative · entry 5 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,884 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 10,293 | $34.66 | $356,755.38 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · nonDerivative · entry 4 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,865 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 1,978 | $34.66 | $68,557.48 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · nonDerivative · entry 3 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,158 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 25, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 3,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · nonDerivative · entry 2 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,136 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 25, 2015 Filed Feb 27, 2015 23:27 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionCommon Stock | 32,939 | $17.69 | $582,690.91 |
DisclosureSEC source: 0001225208-15-006193 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2015 Filed Feb 27, 2015 23:27 UTC |
BOURLA ALBERTGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 15,484 | $0.00 Strike: $17.69 | $0.00 |
DisclosureSEC source: 0001225208-15-006192 · doc4.xml · derivative · entry 7 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,484 shares Expires 2015-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.